This model may apply specifically to the context of leukemic progression of SCN involving acquisition of CSF3R and RUNX1 mutations but could also be relevant to other forms of AML (e.g., with RUNX1 mutations and/or secondary to BM failure syndromes other than SCN). Here, RUNX1 is linked to acute myeloid leukemia.